loading
Verrica Pharmaceuticals Inc stock is traded at $0.86, with a volume of 265.61K. It is up +3.16% in the last 24 hours and down -46.26% over the past month. Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
See More
Previous Close:
$0.8335
Open:
$0.8355
24h Volume:
265.61K
Relative Volume:
0.28
Market Cap:
$37.76M
Revenue:
$5.12M
Net Income/Loss:
$-67.00M
P/E Ratio:
-1.6285
EPS:
-0.5281
Net Cash Flow:
$-38.94M
1W Performance:
-10.61%
1M Performance:
-46.26%
6M Performance:
-90.08%
1Y Performance:
-75.50%
1-Day Range:
Value
$0.8055
$0.8725
1-Week Range:
Value
$0.7919
$0.9999
52-Week Range:
Value
$0.7043
$11.41

Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile

Name
Name
Verrica Pharmaceuticals Inc
Name
Phone
484-453-3300
Name
Address
10 NORTH HIGH STREET, WEST CHESTER, PA
Name
Employee
100
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
VRCA's Discussions on Twitter

Compare VRCA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
VRCA 0.8725 37.76M 5.12M -67.00M -38.94M -0.5281
VRTX 467.20 119.83B 10.63B -479.80M -1.35B 13.33
REGN 760.34 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 565.93 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.51 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.13 24.08B 3.30B -501.07M 1.03B 11.54

Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-25-23 Upgrade Needham Hold → Buy
Mar-22-23 Initiated Jefferies Buy
Feb-13-23 Upgrade RBC Capital Mkts Sector Perform → Outperform
May-25-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
May-14-21 Initiated RBC Capital Mkts Outperform
Dec-24-20 Reiterated H.C. Wainwright Buy
Jul-15-20 Downgrade BofA Securities Buy → Neutral
Jun-30-20 Reiterated H.C. Wainwright Buy
Jun-24-20 Initiated Northland Capital Outperform
Mar-24-20 Initiated Needham Buy
Feb-21-19 Initiated H.C. Wainwright Buy
View All

Verrica Pharmaceuticals Inc Stock (VRCA) Latest News

pulisher
Nov 15, 2024

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World

Nov 15, 2024
pulisher
Nov 13, 2024

Verrica Pharmaceuticals' SWOT analysis: navigating challenges in dermatology stock - Investing.com

Nov 13, 2024
pulisher
Nov 12, 2024

Q1 Earnings Forecast for VRCA Issued By HC Wainwright - Defense World

Nov 12, 2024
pulisher
Nov 10, 2024

Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to “Neutral” at HC Wainwright - Defense World

Nov 10, 2024
pulisher
Nov 10, 2024

Verrica downgraded to sector perform by RBC Capital - MSN

Nov 10, 2024
pulisher
Nov 09, 2024

Verrica Pharmaceuticals Reports Q3 2024 Financials and Restructuring Plans - MSN

Nov 09, 2024
pulisher
Nov 09, 2024

Verrica Pharmaceuticals’ (VRCA) Hold Rating Reaffirmed at Needham & Company LLC - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

Biotech Alert: Searches spiking for these stocks today - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Verrica Pharmaceuticals Announces Leadership Transition and Financial Results for Q3 2024 - Defense World

Nov 07, 2024
pulisher
Nov 06, 2024

Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to "Neutral" at HC Wainwright - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

RBC Capital Downgrades Verrica Pharmaceuticals (VRCA) - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Verrica Pharmaceuticals Reports Q3 2024 EPS of -$0.49 and Revenue of -$1.9 Million, Misses Estimates - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Verrica Pharmaceuticals stock hits 52-week low at $0.93 - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

U.S. Stock market: Bluejay Diagnostics (+105.33%), Zoomcar Holdings (+180.40%), and Verrica Pharmaceuticals(+39.10%) among the most volatile stocks during mid day trading - Business Upturn

Nov 05, 2024
pulisher
Nov 05, 2024

Verrica Pharmaceuticals stock hits 52-week low at $0.93 By Investing.com - Investing.com South Africa

Nov 05, 2024
pulisher
Nov 05, 2024

U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn

Nov 05, 2024
pulisher
Nov 05, 2024

Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September - Benzinga

Nov 05, 2024
pulisher
Nov 05, 2024

Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Quarterly Earnings Results - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded to Sector Perform Rating by Royal Bank of Canada - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Verrica Pharmaceuticals Appoints Jayson Rieger as New CEO - Marketscreener.com

Nov 05, 2024
pulisher
Nov 04, 2024

Verrica Pharmaceuticals earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada

Nov 04, 2024
pulisher
Nov 04, 2024

Shares of Verrica Pharmaceuticals Tumble Following 3Q Results, Operational Changes - MarketWatch

Nov 04, 2024
pulisher
Nov 04, 2024

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition - GlobeNewswire

Nov 04, 2024
pulisher
Nov 04, 2024

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership - The Bakersfield Californian

Nov 04, 2024
pulisher
Nov 04, 2024

Verrica Pharmaceuticals Undergoes Leadership and Financial Restructuring - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

Botanix Pharmaceuticals Poised for Market Impact with Sofdra Launch - MSN

Nov 04, 2024
pulisher
Oct 30, 2024

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - Defense World

Oct 30, 2024
pulisher
Oct 28, 2024

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Expands By 24.8% - MarketBeat

Oct 28, 2024
pulisher
Oct 24, 2024

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - GlobeNewswire

Oct 24, 2024
pulisher
Oct 22, 2024

Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection - Law360

Oct 22, 2024
pulisher
Oct 21, 2024

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Verrica Pharmaceuticals (NASDAQ:VRCA) Given New $10.00 Price Target at TD Cowen - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Verrica shares price target cut by TD Cowen - Investing.com Canada

Oct 21, 2024
pulisher
Oct 11, 2024

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc.VRCA - Business Wire

Oct 11, 2024
pulisher
Oct 10, 2024

GLP-1 Receptor Agonist Market Set to Witness Significant Growth by 2024-2031:Verrica Pharmaceuticals, AbbVie - EIN News

Oct 10, 2024
pulisher
Oct 09, 2024

Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Verrica Pharmaceuticals reports board changes, non-compliance - Investing.com India

Oct 09, 2024
pulisher
Oct 09, 2024

Verrica Pharmaceuticals reports board changes, non-compliance By Investing.com - Investing.com Australia

Oct 09, 2024
pulisher
Oct 08, 2024

Recent Insider Activity Could Benefit Verrica Pharmaceuticals Inc (VRCA) - Knox Daily

Oct 08, 2024
pulisher
Oct 08, 2024

Verrica Pharmaceuticals Strives for Nasdaq Compliance - TipRanks

Oct 08, 2024
pulisher
Oct 07, 2024

Optinose Names Terry Kohler as CFO - MarketWatch

Oct 07, 2024
pulisher
Oct 07, 2024

Optinose names Terry Kohler as new CFO By Investing.com - Investing.com UK

Oct 07, 2024
pulisher
Oct 07, 2024

Optinose Appoints Terry Kohler as Chief Financial Officer - Marketscreener.com

Oct 07, 2024
pulisher
Oct 07, 2024

The Significance of Moving Averages in Verrica Pharmaceuticals Inc Inc. (VRCA) Price Performance - The InvestChronicle

Oct 07, 2024
pulisher
Oct 07, 2024

Verrica Pharmaceuticals Inc (VRCA)’s stock price range in the last year - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Financial Fitness Check: Examining Verrica Pharmaceuticals Inc (VRCA)’s Key Ratios - The Dwinnex

Oct 07, 2024
pulisher
Oct 04, 2024

Verrica Pharmaceuticals Inc [VRCA] Shares Fall Approximately -61.64% Over the Year - Knox Daily

Oct 04, 2024
pulisher
Oct 04, 2024

Verrica Pharmaceuticals Inc [VRCA] Revenue clocked in at $13.91 million, down -80.19% YTD: What’s Next? - The DBT News

Oct 04, 2024
pulisher
Oct 04, 2024

Royal Bank of Canada Cuts Verrica Pharmaceuticals (NASDAQ:VRCA) Price Target to $11.00 - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

This Tractor Supply Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - MSN

Oct 03, 2024
pulisher
Oct 03, 2024

Verrica downgraded to hold by Needham, cash position cited - MSN

Oct 03, 2024

Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.04
price down icon 0.87%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):